On June 5, Lupin announced that the U.S. Food and Drug Administration (“FDA”) approved RANLUSPEC, a ranibizumab biosimilar to Genentech’s LUCENTIS®. RANLUSPEC, which received European Marketing Authorization earlier this year, is indicated for the treatment of neovascular (wet) age-related macular degeneration and other retinal vascular disorders. It is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes (PFS). RANLUSPEC is now the fourth FDA-approved ranibizumab biosimilar and Lupin’s second biosimilar approved in the United States.
